Myelofibrosis

Welcome to The Myelofibrosis Channel

Stay up-to-date with the latest news on this rare bone marrow malignancy with our expert-led video interviews, as well as podcasts and roundtable discussions. The Myelofibrosis Channel covers different pathways that have been explored to modify myelofibrosis, including novel agents directed at various targets such as pacritinib, momelotinib, parsaclisib, navtemadlin, tagraxofusp, and much more.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter